Taurine is one of the most abundant amino acids in mammalian tissues. It is obtained from the diet and by de novo synthesis, from cysteic acid or hypotaurine. Despite the discovery in 1954 that the oxygenation of hypotaurine produces taurine, the identification of an enzyme catalyzing this reaction has remained elusive. In large part this is due to the incorrect assignment, in 1962, of the enzyme as a NAD-dependent hypotaurine dehydrogenase. For more than 55 years the literature has continued to refer to this enzyme as such. Here we show, both in vivo and in vitro, that the enzyme that oxygenates hypotaurine to produce taurine is flavin-containing monooxygenase 1 (FMO1). Metabolite analysis of the urine of Fmo1-null mice by 1 H NMR spectroscopy revealed a build-up of hypotaurine and a deficit of taurine in comparison with the concentrations of these compounds in the urine of wild-type mice. In vitro assays confirmed that FMO1 of human catalyzes the conversion of hypotaurine to taurine utilizing either NADPH or NADH as co-factor. FMO1 has a wide substrate range and is best known as a xenobiotic-or drug-metabolizing enzyme. The identification that the endogenous molecule hypotaurine is a substrate for the FMO1catalyzed production of taurine resolves a long-standing mystery. This finding should help establish the role FMO1 plays in a range of biological processes in which taurine or its deficiency is implicated, including conjugation of bile acids, neurotransmitter, anti-oxidant and anti-inflammatory functions, the pathogenesis of obesity and skeletal muscle disorders.
Introduction
Taurine (2-aminoethanesulfonic acid) is one of the most abundant amino acids in mammalian tissues (1) . It is an organic osmolyte involved in cell volume regulation (1) and has a variety of cytoprotective and developmental roles, particularly in neurological and ocular tissues (2) . It is also involved in the formation of bile salts (1) and the modulation of intracellular calcium concentration (3) . Taurine is considered an essential substance in mammals and its deficiency has been implicated in several pathological conditions; however, the mechanism by which the amino acid exerts its effects is not understood.
Taurine is obtained from the diet and, by de novo synthesis, from cysteic acid (4) or hypotaurine (5) . Hypotaurine is itself an organic osmolyte and cytoprotective agent (6) and acts as an anti-oxidant to scavenge highly reactive hydroxyl radicals (7) .
The oxygenation of hypotaurine to produce taurine was discovered in 1954 (5) . Later the enzyme that converts hypotaurine to taurine was reported to be an NADdependent hypotaurine dehydrogenase (8) , but was not isolated or characterized.
Subsequently, Oja et al. (9) noted that the production of taurine in tissue extracts was optimal at pH 9.0 and was stimulated by oxygenation. These authors concluded that the enzyme that converts hypotaurine to taurine was not an NAD-dependent hypotaurine dehydrogenase. By overlooking the work of Oja et al. (9) , and giving credence to the earlier study (8) , the enzyme that catalyzes the conversion of hypotaurine to taurine has continued to be reported as a hypotaurine dehydrogenase, utilising NAD as cofactor (EC 1.8.1.3). Because an enzyme that catalyzes the reaction has not been identified or isolated, the conversion of hypotaurine to taurine has sometimes been referred to as non-enzymatic. 4 Here we show, both in vivo, through the use of a knockout-mouse line, and in vitro, by assays of human enzymes, that oxygenation of hypotaurine to produce taurine is catalyzed by flavin-containing monooxygenase 1 (FMO1).
Results
Previous phenotypic analysis (10) (11) (12) (13) has identified metabolic differences between mice in which the Fmo1, Fmo2 and Fmo4 genes had been deleted (Fmo1 -/-, 2 -/-, 4 -/mice) (10) and wild-type animals. As an extension of this work we have used one-dimensional (1D) 1 H NMR spectroscopy to compare the urinary metabolic profiles of the knockout mouse line and wild-type animals. Analysis of the urine of male and female Fmo1 -/-, 2 -/-, 4 -/mice revealed signals at 2.66 and 3.37 ppm, corresponding to those of hypotaurine. Such signals were markedly lower in the urine of wild-type mice (Fig. 1A, B ). Signals at 3.28 and 3.43 ppm, corresponding to those of taurine, were detected in the urine of both wild-type and Fmo1 -/-, 2 -/-, 4 -/mice, but their intensities were lower in the latter (Fig. 1A, B ). The identities of taurine and hypotaurine in urine samples were confirmed by two-dimensional (2D) NMR (Supporting Information Fig. S1 ). The urinary ratio of taurine to hypotaurine + taurine was significantly less in Fmo1 -/-, 2 -/-, 4 -/mice than in wild-type mice (P <0.0001) ( Fig. 1C ). The build-up of hypotaurine and the concomitant decrease of taurine in the urine of Fmo1 -/-, 2 -/-, 4 -/mice ( Fig. 1A, B , C) suggests that the formation of taurine from hypotaurine is catalyzed by an FMO.
Of the three genes deleted in the knockout mouse, the gene encoding FMO4 is expressed at very low levels in mouse (14) and human (15) , and that encoding FMO2 is expressed in low amounts in mouse (14) and, in most humans, the gene does not encode a functional protein because of the presence of a premature stop codon (16) . In 5 contrast, the gene encoding FMO1 is relatively highly expressed in a number of tissues in both mouse (14) and human (15) . Therefore, in humans the most likely candidate for catalyzing the oxygenation of hypotaurine to produce taurine is FMO1.
To investigate whether this was the case, baculosomes containing recombinantly expressed human FMO1 were incubated with hypotaurine and the cofactor NADPH at pH 8.5, the optimum for FMO1, and at the more physiological pH of 7.4. Analysis of reaction products by 1D 1 H NMR spectroscopy identified signals at 3.276 and 3.433 ppm, corresponding to taurine, at both pHs ( Fig. 2A ). As expected of an FMO1catalyzed reaction, with NADPH as cofactor, production of taurine was greater at pH 8.5 than at pH 7.4 (P <0.01) ( Fig. 2B ). In comparison, very little taurine was detected in incubations of control insect cell microsomes at pH 8.5 and none at pH 7.4 ( Fig.   2A , B). The identity of taurine as a product of FMO1-catalyzed reactions was confirmed by high-resolution UPLC-electrospray mass spectrometry against an authentic reference standard ( Fig. S2 ) (17) .
We also investigated whether the conversion of hypotaurine to taurine could be catalyzed by either of the two other major functional FMOs of humans, FMO3 and FMO5 (18) . In comparison with baculosomes containing human FMO1, those containing FMO3 produced much lower amounts of taurine at pH 8.5 or 7.4, with either NADPH or NADH as cofactor (P <0.01). Production of taurine by baculosomes containing human FMO5 was significantly less than by FMO3-baculosomes (P <0.05) and was similar to that produced by control insect cell microsomes (Fig. 2B ).
These results confirm that production of taurine from hypotaurine can be catalyzed by FMO1 and, to a much smaller extent, by FMO3, but not significantly by FMO5.
The production of taurine in the Fmo1-null mice was less affected in females (~55% depletion) than in males (~70% depletion) (P <0.0001) (Fig. 1C ). This gender 6 difference is likely due to the contribution in female Fmo1-null mice of FMO3, which is absent from the liver of adult male mice (14, 19) . In the case of wild-type mice, the presence of FMO1, which is more effective than FMO3 in catalyzing the formation of taurine from hypotaurine, as evidenced by analysis in vitro (Fig. 2B) , greatly outweighs the effect of the presence in females of FMO3.
FMOs, despite being termed NADPH-dependent monooxygenases, have been reported to be able also to use NADH as a cofactor (20) . We found that in catalyzing the production of taurine from hypotaurine, FMO1 could use either NADPH or NADH as cofactor ( Fig. 2B ). However, whereas NADPH is the more effective cofactor at pH 8.5 (P <0.01), at pH 7.4 the cofactors are equally effective ( Fig. 2B ).
When NAD was used as cofactor for FMO1 the amount of taurine produced was very low and not significantly different from that produced in the absence of cofactor ( 
Discussion
We have confirmed both in vivo, by 1 H NMR metabolite profiling of the urine of Fmo1 -/-, 2 -/-, 4 -/mice, and in vitro, by analysis of the catalytic activity of FMOs of humans, that formation of taurine from hypotaurine is catalyzed by FMO1, a monooxygenase, and that the enzyme can utilize either NADPH or NADH as cofactor. Our results from knockout mice show that in the absence of FMO1 most taurine production is abolished in both males and females, suggesting that the major source of this abundant amino acid is the FMO1-catalyzed oxygenation of hypotaurine ( Fig. 4 ). Consistent with this, the lack of production of taurine from hypotaurine in vitro in the absence of enzyme indicates that non-enzymatic conversion does not contribute substantially to taurine production.
FMOs (EC 1.14.13.8) are best known for their role in the metabolism of xenobiotics, including therapeutic drugs (reviewed in (21) ) and foreign chemicals such as organophosphate insecticides (reviewed in (22)). Of the members of the FMO family, FMO1 has the broadest substrate range (reviewed in (22)). In addition to its role in xenobiotic metabolism, FMO1 has been identified as a novel regulator of energy balance (12) .
In humans, FMO1 is expressed in a range of tissues in which the action of taurine has been implicated, for example, kidney (15), brain (23), small intestine (24), heart (25) and a number of endocrine tissues, including pancreas, adrenal and testis (23) . In human liver, FMO1 is expressed in the fetus, but is switched off after birth 8 (15, 26, 27) . This pattern of expression is consistent with the decline in taurine concentration in the liver after birth (28) . In contrast, in adult rodent liver, the gene encoding FMO1 is highly expressed (14) and taurine is abundant (9) .
Concentrations of taurine are high in human and monkey fetal brain, but fall during development (28) . The decline in taurine concentration in developing brain is consistent with the decrease in expression of Fmo1 in mouse brain during development (14) . FMO1 is active in mouse brain, as evidenced by its catalysis of the N-oxygenation of the tricyclic antidepressant imipramine (10) . FMO1 would therefore be expected to contribute to the production in brain of taurine from the precursor hypotaurine.
Taurine deficiency is implicated in a number of pathological conditions, including cardiomyopathy, muscular abnormalities and renal dysfunction (2) .
Conversely, taurine supplementation has been reported to have positive effects on health, for instance, in lowering total plasma cholesterol (29) and in overcoming insulin resistance (2) . Given our finding that FMO1 catalyzes the formation of taurine from hypotaurine it is of interest that Fmo1-null mice exhibit some characteristics in common with those of taurine deficiency: raised plasma concentrations of cholesterol (13) and glucose (12) .
The KM of FMO1 for hypotaurine is similar to that of cysteine dioxygenase of human, an upstream enzyme in the taurine biosynthetic pathway (Fig.   4 ), for its substrate cysteine (30) . Although the KM for the FMO1-catalyzed oxygenation of hypotaurine is high, our results from the knockout-mouse line indicate that FMO1 is physiologically relevant for the production of taurine.
In addition to Fmo1, two other genes are deleted in the knockout mouse line, Fmo2 and Fmo4. Most humans are homozygous for a nonsense mutation of FMO2, 9 c.1414C>T[p.(Gln472*)], the FMO2*2A allele, and do not express functional FMO2 (16, 31) , and in the case of FMO4 the gene is expressed at very low levels (15) . Thus, although we cannot eliminate the possibility that FMO2 or FMO4 are able to catalyze hypotaurine oxygenation in vitro, neither of these enzymes is likely to contribute substantially to the production of taurine in humans in vivo.
Commensurate with a role for FMO1 in endogenous metabolism, the gene contains few non-synonymous polymorphisms (32) , each of which is present at very low frequency (33) and only one has a significant, but substrate-dependent, effect on catalytic activity (34) . However, inter-individual variation of up to 5-fold in the expression of FMO1 in adult human tissues such as kidney (35) and small intestine (24) could affect taurine production and thus contribute to an intracellular deficiency of the amino acid. In addition, the involvement of FMO1 in the metabolism of drugs implies that drug substrates of the enzyme would compete with hypotaurine for available enzyme and thus compromise taurine production, leading to potentially adverse effects on general health and therapeutic response.
Experimental procedures
Animals: All mice used in this study were bred at University College London. The Fmo1 -/-, 2 -/-, 4 -/mouse line was constructed as described previously (10, 36) . Mice were genotyped as described (37) . Mice were given free access to food (a standard Sample preparation for NMR spectroscopy: Urine samples (50 µl) were prepared for NMR spectroscopy as described previously (39) . Enzyme assay samples were thawed, vortexed, then 160 µl of sample was mixed with 80 µl of 0.6 M phosphate buffer, as described previously (39) . The samples were re-vortexed and centrifuged at 13 000 g for 5 min at 4 0 C. Supernatant (200 µl) was then pipetted into 3.0-mm outer diameter (o.d.) SampleJet NMR tubes (Norell, S-3.0-500-1).
NMR spectroscopic analysis: 1 H NMR spectra of urine and enzyme assay samples
were recorded on a Bruker Avance III spectrometer (Bruker BioSpin GmbH, 12 Rheinstetten, Germany) operating at 600.44 MHz and at a temperature of 300.0 K, using a standard 1D NOESY presaturation pulse sequence with gradient pulses (noesygppr1d), as described previously (39) .
NMR spectral processing was carried out in MNova (MestReNova, version 12.0.1-20560, Mestrelab Research S.L.). The deconvolution of the peaks for metabolite quantification was done using the MNova GSD algorithm. The peak areas were obtained, and the residuals were manually minimized by adjusting the fitting parameters of each peak. Data were imported into Matlab (R2014b, MathWorks).
Statistical analysis was performed using an unpaired two-tailed t-test. Significance level P < 0.05.
NMR data deposition:
Original NMR data will be deposited in MetaboLights (EBI UK) (40) after publication.
Metabolite identification: NMR-based metabolite identification was carried out using standard methods, as described (17) , and using information from the literature and public databases including the Human Metabolite Database (41) (HMDB, http://www.hmdb.ca/).2018). Hypotaurine in Fmo1 -/-, 2 -/-, 4 -/mouse urine showed the following features: 2.665 (t, 6.9 Hz), 58.6 (HSQC) with HMBC to 36.4 and COSY (see Fig. S1 ) to 3.365 (t, 6.9 Hz), 36 
